Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR)… Read more
Ensysce Biosciences Inc (ENSC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -2.133x
Based on the latest financial reports, Ensysce Biosciences Inc (ENSC) has a cash flow conversion efficiency ratio of -2.133x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.87 Million) by net assets ($874.71K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ensysce Biosciences Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Ensysce Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Ensysce Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ensysce Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nocera Inc
NASDAQ:NCRA
|
-0.164x |
|
Altura Mining Limited
PINK:ALTAF
|
-0.075x |
|
CIMERWA PLC
RSE:CMR
|
N/A |
|
Asia Biomass Public Company Limited
BK:ABM
|
0.010x |
|
Techindia Nirman Limited
NSE:TECHIN
|
-0.161x |
|
Athena Resources Ltd
AU:AHN
|
-0.019x |
|
Kim Hin Joo
KLSE:0210
|
0.157x |
|
Merafe
JSE:MRF
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Ensysce Biosciences Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Ensysce Biosciences Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $3.38 Million | $-7.50 Trillion | -2219773.789x | -13410747.77% |
| 2023-12-31 | $-651.27K | $-10.78 Million | 16.552x | +272.89% |
| 2022-12-31 | $-4.03 Million | $-17.89 Million | 4.439x | +339.37% |
| 2021-12-31 | $-8.16 Million | $-8.24 Million | 1.010x | +439.31% |
| 2020-12-31 | $-6.66 Million | $-1.25 Million | 0.187x | +217.21% |
| 2019-12-31 | $186.17 Million | $10.99 Million | 0.059x | +1041.43% |
| 2018-12-31 | $197.39 Million | $-1.24 Million | -0.006x | -386.42% |
| 2017-12-31 | $195.27 Million | $-251.83K | -0.001x | -- |